“Most people should take fish oil or omega-3 supplements.”
Most people do not need a fish-oil supplement: in a large trial of healthy older adults, it did not prevent major heart events or cancer.
Most people do not need a fish-oil capsule. Prescription omega-3 is a different medicine, used for specific conditions such as high triglycerides in people at high heart risk.
If you eat seafood, keep it in your usual meals. If you are thinking about a capsule, know your goal and the dose first, and ask whether there is evidence for your situation.
Safety note: In long-term heart trials, omega-3 supplements raised the risk of atrial fibrillation, an irregular heartbeat, by about 25 percent overall, with a larger rise at doses above 1 gram a day. In REDUCE-IT, the prescription product also led to more hospital stays for atrial fibrillation and a little more serious bleeding. Do not swap a store-bought fish-oil product for prescribed icosapent ethyl.
Talk to a healthcare professional if: you have very high triglycerides, you have atrial fibrillation or a bleeding disorder, you take a blood thinner or antiplatelet medicine, or you have surgery planned and are thinking about a high-dose omega-3 product.
In a large trial of 25,871 healthy older adults, a standard 1 gram daily fish-oil capsule did not lower the main combined heart outcome or cancer, though heart attacks alone were lower, a secondary finding. Confidence is moderate because that is one large trial of one product in older U.S. adults.
Most people do not need a fish-oil supplement: in a large trial of healthy older adults, it did not prevent major heart events or cancer. The grain of truth is that heart attacks alone were 28 percent lower with fish oil, a secondary result rather than the trial's main test.
"Omega-3" covers different products and doses. Store-bought fish oil, a mix of EPA and DHA, is not the same as prescription icosapent ethyl, which is a purified form of EPA. In the REDUCE-IT trial, 4 grams a day of the prescription product lowered heart events in high-risk patients who were already taking statins and had high triglycerides; that result does not apply to the general population, and the drug's maker funded the trial.
- Manson JE, Cook NR, Lee IM, et al. Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer. New England Journal of Medicine. 2019;380:23-32. DOI: 10.1056/NEJMoa1811403. PMID: 30415637. PMCID: PMC6392053
- Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. New England Journal of Medicine. 2019;380:11-22. DOI: 10.1056/NEJMoa1812792. PMID: 30415628
- Gencer B, Djousse L, Al-Ramady OT, et al. Effect of Long-Term Marine Omega-3 Fatty Acids Supplementation on the Risk of Atrial Fibrillation in Randomized Controlled Trials of Cardiovascular Outcomes. Circulation. 2021;144(25):1981-1990. DOI: 10.1161/CIRCULATIONAHA.121.055654. PMID: 34612056. PMCID: PMC9109217